Avicidin cancer therapy data

NERX reported on nine of 11 patients enrolled in the dosimetry monitoring portion of its Phase I trial, announcing an eight-fold improvement in the tumor-to-blood ratio with pre-targeting, compared to conventional use

Read the full 328 word article

How to gain access

Continue reading with a
two-week free trial.